CN102159189B - 用于药物递送的纳米载体 - Google Patents

用于药物递送的纳米载体 Download PDF

Info

Publication number
CN102159189B
CN102159189B CN2009801372511A CN200980137251A CN102159189B CN 102159189 B CN102159189 B CN 102159189B CN 2009801372511 A CN2009801372511 A CN 2009801372511A CN 200980137251 A CN200980137251 A CN 200980137251A CN 102159189 B CN102159189 B CN 102159189B
Authority
CN
China
Prior art keywords
acid
peg
nanocarrier
polymer
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2009801372511A
Other languages
English (en)
Chinese (zh)
Other versions
CN102159189A (zh
Inventor
林杰生
罗君涛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN102159189A publication Critical patent/CN102159189A/zh
Application granted granted Critical
Publication of CN102159189B publication Critical patent/CN102159189B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0082—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion micelle, e.g. phospholipidic micelle and polymeric micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2009801372511A 2008-09-23 2009-09-22 用于药物递送的纳米载体 Active CN102159189B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9927208P 2008-09-23 2008-09-23
US61/099,272 2008-09-23
PCT/US2009/057852 WO2010039496A2 (en) 2008-09-23 2009-09-22 Nanocarriers for drug delivery

Publications (2)

Publication Number Publication Date
CN102159189A CN102159189A (zh) 2011-08-17
CN102159189B true CN102159189B (zh) 2013-06-12

Family

ID=41508806

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801372511A Active CN102159189B (zh) 2008-09-23 2009-09-22 用于药物递送的纳米载体

Country Status (5)

Country Link
US (2) US9579400B2 (enExample)
EP (1) EP2344134B1 (enExample)
JP (1) JP5539993B2 (enExample)
CN (1) CN102159189B (enExample)
WO (1) WO2010039496A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008141230A1 (en) 2007-05-09 2008-11-20 Lawrence Livermore National Security, Llc Methods and systems for monitoring production of a target protein in a nanolipoprotein particle
WO2012158622A2 (en) 2011-05-13 2012-11-22 The Regents Of The University Of California Reversibly crosslinked micelle systems
ES2683377T3 (es) 2011-07-29 2018-09-26 Avelas Biosciences, Inc. Moléculas de suministro selectivo y métodos de uso
US8895055B2 (en) * 2011-12-21 2014-11-25 The Regents Of The University Of California Telodendrimer nanodiscs without apolipoprotein
US9644038B2 (en) 2011-12-21 2017-05-09 The Regents Of The University Of California Apolipoprotein nanodiscs with telodendrimer
EP2793953B1 (en) * 2011-12-21 2019-12-04 The Regents of The University of California Telodendrimers with enhanced drug delivery
MX374014B (es) * 2012-05-16 2020-07-24 Mewa Singh Composiciones farmaceuticas para la entrega de farmacos insolubles en agua.
US9642916B2 (en) * 2012-12-12 2017-05-09 The Regents Of The University Of California Porphyrin modified telodendrimers
CA3128911C (en) 2013-01-30 2023-10-17 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
US11406714B2 (en) * 2013-08-21 2022-08-09 The Research Foundation For The State University Of New York Telodendrimers and nanocarriers and methods of using same
EP3204048A4 (en) * 2014-10-07 2018-06-27 The Research Foundation for the State University of New York Functional segregated telodendrimers and nanocarriers and methods of making and using same
WO2016168607A1 (en) * 2015-04-15 2016-10-20 University Of Tennessee Research Foundation Compositions and methods of muc13 antibodies for cancer treatment and diagnosis
TW201706312A (zh) * 2015-05-20 2017-02-16 免疫功坊股份有限公司 用以治療疾病的分子構建體
EP3277663A4 (en) * 2015-07-20 2019-01-02 ST Pharm Co. Ltd. Novel drug delivery conjugated moiety for oral administration of drug unsuitable for oral administration and preparation method thereof
US12226529B2 (en) 2015-08-25 2025-02-18 Lawrence Livermore National Security, Llc Stable nanolipoprotein particles and related compositions methods and systems
JP2018527350A (ja) * 2015-09-01 2018-09-20 イミュンワーク インク．Ｉｍｍｕｎｗｏｒｋ Ｉｎｃ． 血餅形成の予防及び／又は血栓症の治療のための分子構築物
WO2017044899A1 (en) 2015-09-11 2017-03-16 Lawrence Livermore National Security, Llc Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation
CN108601949A (zh) * 2016-01-14 2018-09-28 加利福尼亚大学董事会 用llp2a-二膦酸盐化合物治疗骨坏死的方法
JP7102005B2 (ja) 2016-09-15 2022-07-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 改善されたハイブリッドテロデンドリマー
CN108159422B (zh) * 2016-12-07 2020-09-15 上海时莱生物技术有限公司 一种自组装载药系统及其复合制剂的制备方法
WO2018136778A1 (en) 2017-01-19 2018-07-26 The Research Foundation For The State University Of New York Telodendrimers with riboflavin moieties and nanocarriers and methods of making and using same
WO2018160759A1 (en) * 2017-02-28 2018-09-07 The Research Foundation For The State University Of New York Zwitterionic dendritic amphiphiles, zwitterionic dendrimers, zwitterionic telodendrimers, nanocarriers comprising same, and methods of making and using same
US11207422B2 (en) 2017-05-02 2021-12-28 Lawrence Livermore National Security, Llc MOMP telonanoparticles, and related compositions, methods and systems
US12083223B2 (en) 2017-05-02 2024-09-10 Lawrence Livermore National Security, Llc Nanolipoprotein particles and related compositions methods and systems for loading RNA
WO2019079277A1 (en) * 2017-10-16 2019-04-25 Dynamic Biologics Inc. POLYMERIC COMPOSITIONS OF MONOMETHYL FUMARATE FOR THE TREATMENT OF RECURRENT-REMEDY PLAQUE SCLEROSIS AND PSORIASIS
CN107955153B (zh) * 2017-11-29 2020-12-15 南京拉克森生物医药科技有限公司 一种聚乙二醇-去氧胆酸及其衍生物的制备方法和应用
CN115811991A (zh) * 2019-08-14 2023-03-17 加利福尼亚大学董事会 用于癌症免疫治疗的智能肽和可转化纳米颗粒
US20230076792A1 (en) * 2019-12-17 2023-03-09 The Regents Of The University Of California Sequential targeting in crosslinking nano-theranostics for treating brain tumors
CN111189747B (zh) * 2020-01-05 2022-03-29 天津大学 一种针对颗粒聚结成球技术的三元溶剂体系筛选方法
KR20210122492A (ko) * 2020-04-01 2021-10-12 에스티팜 주식회사 항암 요법을 위한 헤파린-담즙산 올리고머 컨쥬게이트
CN112679504B (zh) * 2020-12-24 2022-04-19 河北工业大学 两亲性共轭寡聚物及其制备及利用其自组装制备得到的载药纳米粒子
CN119661825B (zh) * 2023-09-19 2025-11-14 上海交通大学 聚两性离子-胆酸及其合成以及其在药物递送中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1310612A (zh) * 1998-05-20 2001-08-29 利普索姆公司 新型颗粒制剂
US6365191B1 (en) * 1999-02-17 2002-04-02 Dabur Research Foundation Formulations of paclitaxel, its derivatives or its analogs entrapped into nanoparticles of polymeric micelles, process for preparing same and the use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020041898A1 (en) 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
AU2002953073A0 (en) 2002-11-21 2003-01-16 Access Pharmaceuticals Australia Pty Limited Amplification of biotin-mediated targeting
KR100578382B1 (ko) * 2004-07-16 2006-05-11 나재운 항암제의 전달체용 수용성 키토산 나노입자 및 그 제조방법
US7846893B2 (en) 2005-02-16 2010-12-07 Rutgers, The State University Of New Jersey Drug-polymer conjugates coupled to a peptidic carrier
AU2006336311B2 (en) 2006-01-19 2013-01-24 Allexcel, Inc. Solubilization and targeted delivery of drugs with self-assembling amphiphilic polymers
AU2007296190A1 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Lysine-based polymeric linkers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1310612A (zh) * 1998-05-20 2001-08-29 利普索姆公司 新型颗粒制剂
US6365191B1 (en) * 1999-02-17 2002-04-02 Dabur Research Foundation Formulations of paclitaxel, its derivatives or its analogs entrapped into nanoparticles of polymeric micelles, process for preparing same and the use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DUNCAN R.THE DAWNING ERA OF POLYMER THERAPEUTICS.《NATURE REVIEWS. DRUG DISCOVERY》.2003,第2卷(第1期),347-360. *
RUXANDRA GREF ET AL.Biodegradable Long-Circulating Polymeric Nanospheres.《SCIENCE》.1994,第263卷(第5153期),1600-1603. *
VIJAYALAKSHMI N ET AL.A simple construction of a bile acid based dendritic light harvesting system.《ORGANIC LETTERS》.2005,第7卷(第13期),2727-2730. *
YILONG CHEN ET AL.Fluorescence study of inclusion complexes between star-shaped cholic acid derivatives and polycyclic aromatic fluorescent probes and the size effects of host.《JOURNAL OF PHYSICAL CHEMISTRY B》.2008,第112卷(第11期),3402-3409. *

Also Published As

Publication number Publication date
JP2012503603A (ja) 2012-02-09
EP2344134A2 (en) 2011-07-20
CN102159189A (zh) 2011-08-17
JP5539993B2 (ja) 2014-07-02
WO2010039496A3 (en) 2010-07-01
EP2344134B1 (en) 2017-11-08
US9579400B2 (en) 2017-02-28
WO2010039496A2 (en) 2010-04-08
US20110286915A1 (en) 2011-11-24
US20170290921A1 (en) 2017-10-12
US10556021B2 (en) 2020-02-11

Similar Documents

Publication Publication Date Title
CN102159189B (zh) 用于药物递送的纳米载体
US11192978B2 (en) Reversibly crosslinked micelle systems
US9642916B2 (en) Porphyrin modified telodendrimers
Zhang et al. A pH-sensitive nanosystem based on carboxymethyl chitosan for tumor-targeted delivery of daunorubicin
Mohammadifar et al. Polyamidoamine and polyglycerol; their linear, dendritic and linear–dendritic architectures as anticancer drug delivery systems
US10406233B2 (en) Telodendrimers with enhanced drug delivery
Gheybi et al. Supramolecular anticancer drug delivery systems based on linear–dendritic copolymers
EP3347053B1 (en) Functional, segregated, charged telodendrimers and nanocarriers and methods of making and using same
KR20140041522A (ko) 약물 전달용 중합체 나노입자
Jin et al. Amphipathic dextran-doxorubicin prodrug micelles for solid tumor therapy
Gatti et al. Hydrazone linked doxorubicin-PLA prodrug nanoparticles with high drug loading
Zhou et al. HPMA polymeric nanocarriers for anticancer drugs with tumor microenvironment-responsive extracellular biodegradation and intracellular drug release
Minko et al. Multifunctional nanotherapeutics for cancer
Ali et al. pH-responsive polymeric micelles for drug delivery
JP6235460B6 (ja) 可逆的に架橋されたミセルｓｙｓｔｅｍｓ
TR2022021916A2 (tr) Nano-i̇laç taşima si̇stemi̇
Bhadra et al. PEGylated Dendritic Nanoparticulate Carriers of Anti-Cancer Drugs
Callari Polymer Nanocarriers to Enhance the Efficiency of Platinum-Based Chemotherapeutics

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant